|
|
|
市場調查報告書
全球自動·快速微生物檢測市場
Automated and Rapid Microbiological Tests
|
全球自動·快速微生物檢測市場 是由出版商Global Industry Analysts, Inc.在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 660 價格從美金4500起跳。
本報告提供全球自動·快速微生物檢測市場相關分析，2009∼2017年的6年分析，加入此市場的主要93家企業的簡介等彙整資料，為您概述為以下內容。
第1章 簡介·調查手法·產品定義
第2章 產業概要
- 今後預測
- 與蟲子的纏鬥歷史促進市場的未來
- 自動微生物學的檢驗:臨床診斷市場上令人不安的灰色地帶
- 傳統的快速微生物檢測面臨消失的命運
- 現在及未來分析
- 宏觀:概要
- 決定未來市場的事項
- 有幾個值得注意的趨勢
- 生化科技和快速微生物檢測
- 目前市場趨勢
- 商務案例
- 在患者旁邊所進行的檢驗
- 優點和缺點
- 人體抗生素抗藥性的在患者旁邊所進行的檢驗所扮演的角色
- 微生物學的即時檢測時期:檢討
- 市場結構
- 競爭趨勢
- 市場結構
第3章 市場趨勢與課題
第4章 市場影響因素
- 病原體源源不絕的生物學戰鬥促進市場成長
- 創新的產品
- 其他的推動市場要素
- 處理時間短的高度需求
- 患者的認識度提高
- STD的發病率上升增加市場接受度
- 超快速HIV篩檢檢驗
- 快速微生物檢測的驗證
- 檢驗條件不符合
- 流感
第5章 產品/技術概要
第6章 最終用途分析
- 臨床檢驗的應用
- STD即時檢測
- 呼吸系統檢驗
- 單核球增多症檢驗
- 鏈球菌檢驗
- 腸胃檢驗
- 非臨床檢驗
- 食品·水的安全性檢驗
- 食品安全檢驗:有利可圖的應用領域
- 醫藥品部門的微生物學的檢驗方法
- 環境檢驗
- 其他的應用
第7章 產品創新·引進
第8章 過去的產品創新·引進
第9章 近幾年的產業活動
第10章 過去的企業活動
第11章 主要企業
- Abbott Laboratories
- Abbott Diagnostics
- Alere Inc.
- Becton Dickinson and Company
- bioMerieux SA
- bioMerieux, Inc.
- Bio-Rad Laboratories, Inc
- Cellabs Pty Ltd
- Celsis International Plc
- Coris BioConcept
- F. Hoffmann-La Roche Ltd.
- Gen-Probe Inc.
- MedMira, Inc.
- Meridian Biosciences, Inc.
- Orasure Technologies, Inc.
- Orion Diagnostica Oy
- Quidel Corp.
- Sekisui Diagnostics (Japan)
- Siemens Healthcare Diagnostics, Inc.
- Thermo Fisher Scientific, Inc.
- Remel, Inc.
- Oxoid Limited
第12章 全球市場預測
第13章 美國市場
第14章 歐洲市場
第15章 其他各國
Abstract
This report analyzes the worldwide markets for Automated and Rapid Microbiological Tests in US$ Million by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 93 companies including many key and niche players such as Abbott Laboratories, Abbott Diagnostics, Alere Inc., Becton Dickinson and Company, bioMerieux SA, bioMerieux, Inc., Bio-Rad Laboratories, Inc., Cellabs Pty Ltd, Celsis International Plc., Coris BioConcept, F. Hoffmann-La Roche Ltd., Gen-Probe Inc., MedMira Inc., Meridian Biosciences, Inc., Orasure Technologies, Inc., Orion Diagnostica Oy, Quidel Corporation, Sekisui Diagnostics, Siemens Healthcare Diagnostics, Inc., Thermo Fisher Scientific, Inc., Remel, Inc., and Oxoid Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- Clinical Applications
- Automated Identification and Susceptibility Systems
- Automated Blood Culture Systems
- Automated Tuberculosis Systems
- Streptococcal Infection Rapid Tests
- GC/Chlamydia Rapid Tests
- Other Automated & Rapid Microbiological Tests
- Non-Clinical Applications
2. INDUSTRY OVERVIEW
- Outlook
- Evolutionary Battle Against Bugs Drives Market Future
- Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics Market
- Traditional Rapid Microbiological Tests Destined to Go Out With the Old
- A Current & Future Analysis
- Segmental Perspective
- Clinical Applications
- Non-Clinical Applications
- Macro: The Big Picture
- Deciding the Market's Future
- A Holistic Peek into a Few Noteworthy Trends
- Biotechnology & Rapid Microbial Tests
- Automated & Rapid Microbiological Tests: "Current Market Stance"
- A Business Case for Automated & Rapid Microbiological Testing
- Near Patient Testing: An Offshoot of Rapid Microbiological Tests
- Pros & Cons of Near Patient Testing
- Role of Near Patient Testing in Reducing Antibiotic Resistance in Humans
- The Pre/Post Microbial Rapid Testing Era: A Review
- Market Structure
- Competitive Setup of the Diverse Automated & Rapid Microbiology Products Market
- Competitive Landscape
- Table 1: World Market for Microorganism Identification and Resistance Tests by Leading Players (2010): Market Share Breakdown of Value Share for BioMerieux; Becton, Dickinson and Co; and Others (includes corresponding Graph/Chart)
- Table 2: World In-Vitro Diagnostics (IVD) Market by Leading Players (2010): Market Share Breakdown for Roche, Siemens, Abbott Diagnostics, Becton Dickinson, Beckman Coulter and Others (includes corresponding Graph/Chart)
- Table 3: World Blood Screening Market by Leading Players (2010): Market Share Breakdown for Gen-Probe/Novartis, Roche, and Others (includes corresponding Graph/Chart)
3. MARKET TRENDS & ISSUES
- Advancements in Molecular Diagnostics - A Boon or a Threat
- Leading Companies in Molecular Diagnostics Market
- Antibiotic Resistant Bacteria Throws the Spotlight On Microbial Testing
- Instant Detection of Pathogens - A New Epoch in the Fight for Survival
- Lower Cost Rapid Tests Built on Multiple Sampling Modalities - Gaining Momentum
- "Time Constraints?" - Rapid Tests to the Rescue
- Rapid HIV Tests: A New Age Diagnostic Weapon Against the Killer Disease
- Accuracy/Reliability of Home HIV Testing: A Bone of Contention
- Development of Near Patient Test Kits: A Market Driven Phenomenon
- Near Patient Test Kits: A Rumination of Possibilities
- Automated Blood Culture Systems: A Winning Edge in the Fight Against Bacteremia
- Leading Food Processors Resort to Rapid Microbiological Testing
- Impact of Food Scares on Rapid Microbiological Tests Market
- Demand for Microbiological Tests & Level of QC in the Food Industry
- Rapid Tests Creating Brighter Avenues in Food Microbiology Testing Market
- Dire Need to Nip Operating Costs Throws the Spotlight on Rapid Tests
- Key Advantages/Benefits of Rapid Microbiological Tests on Food
- Food Packages of the Future Ingrained with Microbial Alert Systems
- Technology Innovations in Rapid Food Microbial Testing: A Historic Brief
- Obtaining Regulatory Approval - A Major Non-Technical Hindrance
4. FACTORS INFLUENCING THE MARKET
- Continuing Biological Warfare with Pathogens Sparks Market Growth
- Innovative Products - A Key Growth Strategy
- Other Market Drivers in a Capsule
- Low Turnaround Times Skyrocket Demand
- Greater Patient Awareness
- Rising Incidence of STDs Kindles Universal Market Acceptance
- Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV-Epidemic
- Validation of Rapid Microbiological Tests: An Imperative Prerequisite
- Non-Conformance to Testing Requirements: A Weighty Concern
- Influenza - Boosting Rapid Test Prospects
5. PRODUCT/TECHNOLOGY OVERVIEW
- Automated & Rapid Microbiological Tests: A Definition
- Benefits of Automated & Rapid Microbiological Tests
- Classification of Rapid Microbiological Test Methods
- How Does a Rapid Test Work?
- Sample Preparation - A Key Procedure
- Automated Identification and Susceptibility Systems
- Automated Blood Culture Systems
- Automated Tuberculosis Systems
- Microminiaturization of Diagnostic Tests: How Is It Effected?
- Advantages of Microminiaturisation:
- Acid-Fast Microscopy - The Forerunner of Rapid Tests
- Gram's Stain: A Time-Honored & Rapid Method to Detect Pathogens in Blood
- Enabling Technologies of Automated & Rapid Microbiological Tests
- Growth-based Technologies
- Viability-based Technologies
- Cellular-Component or Artifact-based Technologies
- Genomics/ Proteomics
- Microarrays/Microfluidics
- DNA Microchips/Probes
- Polymerase Chain Reaction (PCR)
- Immunoassay
- Immunoassay Escalates into Diverse Fields of Diagnostic Testing
- Nucleic Acid Testing (NAT)
- Nucleic Acid Probes
- Signal-Amplified Tests
- Nucleic Acid Amplification Tests
- Traditional Methods with Computer-Aided Imaging
- Combination Methods
6. END-USE APPLICATION ANALYSIS
- Applications in Clinical Investigations
- STD Rapid Tests
- GC/Chlamydia Rapid Tests
- HIV Rapid Tests
- Table 4: Global Prevalence of HIV Infection by Region: 2007 & 2008 (includes corresponding Graph/Chart)
- Table 5: Global HIV Related Deaths by Region: 2007 & 2008 (includes corresponding Graph/Chart)
- Table 6: Global Distribution of HIV Prevalence, Incidence and Mortality: 2008 (includes corresponding Graph/Chart)
- Advantages of Rapid HIV Testing
- Disadvantages of Rapid HIV Testing
- Syphilis Rapid Tests
- Respiratory Rapid Tests
- RSV/ Influenza Rapid Tests
- Tuberculosis Rapid Tests
- Group A beta Hemolytic Streptococcus Rapid Tests
- Mononucleosis Rapid Tests
- Streptococcus Rapid Tests
- Streptococcus A Rapid Tests
- Streptococcus B Rapid Tests
- Gastrointestinal Rapid Tests
- Giardia Lamblia Rapid Tests
- H. Pylori Rapid Tests
- Cryptosporidium Rapid Tests
- C. Difficile Rapid Tests
- Applications in Non-Clinical Investigations
- Food/Water Safety Tests
- Food Safety Testing: A Lucrative Application Area
- Rapid Microbiological Methods in Pharmaceutical Sector
- Limitations of RMMs
- Advantages of RMMs
- Applications in Pharmaceutical Sector
- Environmental Tests
- Other Miscellaneous Applications
7. PRODUCT INNOVATIONS/INTRODUCTIONS
- BioControl Systems Develops PCR for Detecting Non-O157 Serotypes of STEC
- InDevR Introduces New Virus Counter
- MicroPhage Receives Approval from FDA for KeyPath(tm) MRSA/MSSA Blood Culture Test - BT
- Health Canada Approves DuPont's BAX(r) System Real-Time Assay
- Neogen Receives Approval from AOAC for Reveal 2.0 Test
- Life Technologies and University of Pennsylvania School of Veterinary Medicine Introduce TaqMan(r) Salmonella enteritidis Detection Kit
- AdvanDX Obtains 510(k) Clearance from US FDA for GNR Traffic Light(tm) PNA FISH(r)
- Pall Introduces GeneDisc Rapid Microbiology System
- Abbott Laboratories Introduces PLEX-ID(tm) Biothreat Assay
- bioMerieux Receives FDA Clearance for NucliSENS EasyQ MRSA
- BD Launches BD Max(tm) Open System
- Luxcel Biosciences and Mocon Develop GreenLight(tm)900 Series
- Bruker Launches pTD(tm) for Homeland Security
- Hygiena International Launches EnSURE
- Researchers at University of Georgia Develop Pneumonia Diagnostic Test
- BD Diagnostics Obtains Approval from FDA for BD MAX(tm) GBS Assay
- bioMerieux Receives Approval for TEMPO(r) STA from AOAC and AFNOR
- Bruker Introduces MALDI Sepsityper(tm) Kit
- AdvanDx Introduces GNR Traffic Light(tm) PNA FISH(r)
- ZyGEM Launches Microbial Fingerprinting Diagnostic Technology
- BD Diagnostics Launches BD BACTEC(tm) MGIT(tm) 320 Mycobacteria Culture System
- Particle Measuring Systems Launches BioLaz(tm) Real-Time Microbial Monitor
- NanoLogix Launches Quick-Test Product Line
- MOCON Introduces GreenLight(tm) Screening System
- Life Technologies Unveils MicroSEQ(r) Rapid Microbial Identification System
- IDEXX Laboratories Launch Enterolert(r)-DW in Europe
- Alere Rolls Out three Cardiac Testing Solutions
- Millipore Introduces New Milliflex Quantum Rapid Microbiological Test Method
- BD Diagnostics Adds Automated Microbiology Specimen Processor to its Diagnostic Portfolio
- Roche Introduces New Automatic Clinical Laboratory System, Cobas(r)4800
- Thermo Fisher Scientific Launches an Automated Photometric Method
- Thermo Fisher Scientific Introduces Salmonella Rapid Culture Method
- BD Receives FDA Clearance for BD ProbeTec Amplified DNA Assays on BD Viper System
- Oxoid Introduces Xpect(r) Flu A&B
- Oxoid Extends ProSpecT Range
- Oxoid Launches ELISA Systems Test Kits Range
- Oxoid Introduces Brilliance VRE Agar and Brilliance ESBL Agar
- Oxoid Launches RapID Kits
- Inverness Medical Innovations Introduces C. DIFF QUIK CHEK COMPLETETM Rapid Test
- Celsis International Launches Celsis ReACTTM
- Roche Diagnostics Introduces LightCycler(r) Mycobacterium Detection Kit
- bioMerieux Introduces NucliSENS EasyQ(r) HIV-1 v2.0
- Celsis International Unveils RapiScreenTM Beverage
- Siemens Launches MicroScan Synergies plus(r) gram-positive ID/MIC and MIC Combination Panels
- Oxoid Introduces IDEIATM Norovirus
- Oxoid Introduces Salmonella PrecisTM Process
- Remel Offers FDA Approved RPMI 1640 Agar w/MOPS and 2% Glucose
- Oxoid Launches Rapid MDG Broth
- Lonza Introduces microCompass TYMC (Total Yeast and Mould Count) Detection Kit
- Inverness Medical Introduces Determine HIV-1/2 Ag/Ab Combo
- Meridian Bioscience Rolls Out Two New Rapid Tests for Detecting Epstein-Barr Virus
- Oxoid Introduces Staph Plus System for Identifying Staphylococcal Species
8. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST - A PERSPECTIVE BUILDER
- Siemens Healthcare Diagnostics Launches MicroScan(r) WalkAway(r) plus Diagnostic Microbiology Systems
- Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect(tm) test, in US
- bioMerieux Introduces VIDAS(r), an automated Clostridium difficile A & B Toxins Detection Test
- Oxoid Launches Remel Wellcolex(r) Colour Tests for Testing Shigella, E. coli O157 and Salmonella
- Siemens Healthcare Diagnostics Obtains Health Canada Approval for its VERSANT 440 Molecular System
- Oxoid Unveils Remel Xpect(tm) Clostridium Difficile Toxin A/B Test
- Neogen Introduces Soleris System
- ATCC Introduces Authenticult(tm) Quality Control Microbiological Testing Tool
- Bio-Rad Introduces New EBV Kits
- Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test
- Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test
- FDA Clears Usage of TIGRIS(r) System for Testing WNV in Donated Blood
- FDA Approves ImmunoCard STAT!(r) EHEC for Detecting E. coli Infection
- bioMerieux Introduces TEMPO(r) Quality Indicator Testing System
- Biotrace Introduces Tecra Unique Campylobacter Rapid Test
- bioMerieux Introduces TEMPO(r) EB test for Enterobacteriaceae
- Roche Unveils Elecsys TORCH Assays
- Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan
- bioMerieux Develops Advanced Colorimetry(tm) NH Card
- Roche Introduces Rapid LightCycler SeptiFast Sepsis Test across EU
- Oxoid Launches New Rapid Test for Salmonella Detection in Food Products
- Oxoid Unveils New Contact Plate Design
- FDA Approves Fluconazole Susceptibility Tests from BioMerieux
- Polysciences Unveils New Microbiological & Bacterial Detection Applications
- Researchers Develop New Rapid MODS Test for TB Detection
- Dade Behring Unveils Automated Quadriga BeFree System
- FDA Approves Abbott PRISM(r) HBsAg Assay
- Bayer's EHIV Test Receives FDA Clearance
- Gen-Probe Obtains FDA Approval to Use Aptima Test on Additional Specimens
- Roche Diagnostics' cobas TaqScreen MPX Test Receives CE Mark Approval
- Cepheid Introduces Rapid Xpert(r) MRSA Test in Europe
- Bio-Rad Widens Culture Media with Addition of RAPID'Salmonella
- Chemogen Develops New Tuberculosis Rapid Test
- bioMerieux Rolls Out VIDAS(r) LDUO Test
- Zonda Develops New Rapid Test for Chlamydia
- MedMira Launches MiraCare Rapid HIV Test
- STMicroelectronics and Mobidiag Unveil Lab-On-Chip
- Vermicon Launches ScanVIT-Legionella Rapid Test Kit
- New Line of Rapid Microbial Detection Systems from Centrus
- OraSure Rolls Out OraQuick ADVANCE
- Abbott Unveils Automated HCV Test
- ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and Respiratory Pathogens
- Biophage Pharma Offers Service for Microbiological Testing
- bioMerieux Releases New Rapid Test for Nosocomial Infections
- bioMerieux Widens Product Portfolio with Addition of TEMPO(r) System
9. RECENT INDUSTRY ACTIVITY
- Sekisui Chemical Acquires Diagnostic Products Business of Genzyme
- Dynacare Laboratories Acquires Bruker MALDI Biotyper System
- Magellan Biosciences Enters into Partnership with miacom Diagnostics
- Lonza Signs Distribution Agreement with Roche
- BD Enters into Collaboration with Bruker Daltonics
- Seegene Enters into Partnership with Molzym
- bioMerieux Enters into Partnership with Shanghai Institutes for Biological Sciences
- Becton, Dickinson and Company Acquires Global Rights to Market Micro PRO
- Rapid Micro Biosystems Enters Into Partnership with Life Technologies
- DuPont and U.S. Department of Agriculture to Collaborate for New Microbiological Test
- bioMerieux and Biocartis Enter into Partnership
- BD Diagnostics Collaborates with Lonza Group
- Rapid Micro Biosystems Signs Contract with BARDA
- Shimadzu and bioMerieux Enter into Partnership
- Micro Identification Technologies and OSI Optoelectronics Sign Agreement
- Inverness Medical Adopts New Corporate Identity
- Thermo Fisher Acquires Ahura Scientific
- Don Whitley Signs Distribution Agreement with Zisys
- Charm Sciences Acquires MLX Microplate Luminometer Product Line from Dynex Technologies
- Alpha Analytical Acquires Boston Analytical Inc.
- Roche Group Acquires Genentech
- Roche Acquires Innovatis AG
- 3M Takes Over Biotrace International
- Lab21 Buys Majority Stake in Biotec Laboratories
- Vacci-Test Acquires Maxivet
- bioMerieux Acquires PML Microbiologicals
- 3M Acquires Food Diagnostics AS
- Becton, Dickinson and Company Receives License for its GeneOhmTM from Health Canada
- BD Diagnostics Receives CE Marking for BD GeneOhmTM VanR Test
- bioMerieux Bags AOAC Research Institute's Performance- Tested Methods SM Approval
- MedMira Receives Sales Approval of Multiplo HBV/HIV/HCV Rapid Tests Market
- Schering-Plough Inks International Collaboration Agreement with OraSure Technologies
- Roche Selects Quidel's Influenza Test
- Quidel Enters into Global Alliance with bioMerieux
- Premier's QUEST Selects Remel SpectraTM MRSA
- Thermo Fisher Scientific and MedAssets Supply Chain Systems Enter into a Supply Agreement
- Thermo Fisher Scientific Bags FDA Approval for SpectraTM MRSA
- Advantest to Take Over Credence Systems
- DSM Food Specialties to Acquire CMT Srl
- Sysmex Signs Agreement with bioMerieux
- Nanogen Enters into Definitive Agreement with Elitech Group
- Silliker Acquires Majority Stake in EGI Laboratory
- BD Establishes New Rapid Diagnostic Products Manufacturing Facility in China
- Quidel Corporation Obtains CLIA Waiver from US FDA for its QuickVue(R) RSV Test
- Siemens Obtains US FDA Approval for its VERSANT(tm) 440 Molecular System
- bioMerieux to Market Wescor's Customized Slide Stainer Instruments under bioMerieux Brand
- Schering-Plough and OraSure Ink Collaboration Agreement for Developing Rapid Oral HCV Test
- Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-II Blood Screening Test
- Quidel and bioMerieux Form a Long-term Alliance in Rapid Diagnostic Tests
- BD Diagnostics Obtains US FDA Approval for BD GeneOhm(tm) StaphSR Assay
10. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER
- Siemens Acquires Dade Behring
- Concateno Acquires Euromed
- Meridian Bioscience Obtains US FDA Approval for Two New Rapid Tests
- Thermo Fisher Scientific Teams Up with KBA for Expanding its Microbiology Business Division in Lenexa
- OraSure and SCMS Enter into an Agreement for Supplying OraQuick(R) HIV Test to PEPFAR Countries
- Abbott Obtains US FDA Approval for its Fully Automated PRISM(r) HCV Test
- Gen-Probe Obtains US FDA Approval for its PROCLEIX(r) TIGRIS(r) System for Testing Donated Blood
- AdvanDx Ropes In bioMerieux for Distributing its Rapid Diagnostic Tests in US
- 3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests For Detecting HAIs
- Gen-Probe's PROCLEIX(r) TIGRIS(r) System Obtains US FDA Approval for Screening Donated Blood for West Nile Virus
- 3M Acquires Acolyte Biomedica
- Formation of Siemens Medical Solutions Diagnostics
- bioMerieux Bags Contract to Provide VITEK(r) 2 System for Scottish NHS Labs
- bioMerieux Licenses NorChip's HPV Test Technology for Cervical Cancer
- bioMerieux in Strategic Agreement with Cepheid for Sepsis Assays
- 3M Health Care Creates New Medical Diagnostics Unit
- Schering-Plough & OraSure to Develop Rapid Oral HCV Test
- 3M Acquires Biotrace International
- Siemens Acquires DPC
- Oxoid Acquires Microbiology Business Activities of Dako
- Inverness Acquires IDT and Thermo BioStar
- BMD in Agreement with MND for Research on Diagnostic Tests
- Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus Detection Test
- Dutch Government Grants €7.9 Million to FIND
- FIND and Hain to Develop Rapid Test for MDR and XDR TB
- 3M & Gen-Probe Ally for Developing Rapid Molecular Tests for Food Safety
- Bio View Inks Three-Year Distribution Agreement with Abbott Molecular
- Bodycote Acquires Foodscan Laboratories
- Cepheid Bags STTR Funding for Development of Rapid TB Test
- Abbott and Verax in Distribution Agreement for Verax Platelet PGD(r) Test
- BSL Supplies ABBOTT PRISM(r) System to Blood Donor Testing Centers
- Abbott & ARC in Agreement for Automated Blood Screening Tests
- BD to Set Up Production Facility for Rapid Diagnostic Products in China
- BD Diagnostics Delivers STI Testing Products to BioReference
- Meridian Licenses LAMP Diagnostic Test Technology from Eiken
- OraSure Inks Multi-Year Purchase Contract with New York City
- Abbott Inks Single-Source Agreement with Novation for HIV Test
- Neogen Takes Over Centrus International
- Becton, Dickinson and Company Acquires GeneOhm Sciences
- Inverness Medical Innovations Makes a Synergetic Purchase of ACON Laboratories
- Quest Diagnostics Strikes Deal with BD Diagnostics
- Novation Inks Pact with Abbott for Rapid HIV-1/2 Antibody Test
- TREK Diagnostic and Novation Inks Agreement
- Clinton Foundation Inks Agreement with Four Companies to Cut Prices
- Chembio Obtains FDA Approval for HIV 1/2 Stat-Pak and Sure Check HIV 1/2 Rapid Test PMAs
- Roche's LightCycler SeptiFast Test Attains CE Mark
- Zonda Expands Distribution of Products in Europe
- OraSure Wins Rapid HIV Tests Order
- MedMira Secures Orders for Rapid HIV Tests
- Cepheid Collaborates with Foundation for Innovative Diagnostics
- Chembio Obtains Clearance for Rapid HIV Tests in Kenya
- Genesis Bioventures Bags US Patent for Rapid Prion- Detection Assay
- MedMira Obtains CE Mark for MiraCare
- Setema to Distribute Chembio's Rapid HIV Tests in Ethiopia
- Clinton Foundation HIV/AIDS Initiative Selects Chembio to Provide Rapid HIV Tests
- Quidel Acquires immunochemical Fecal Occult Blood Test
- Xact Aid Snaps Up STD Alert
- Grant Life Sciences Acquires Rapid Tests from AccuDx
- Millipore Ties Up with Gen-Probe
- Foundation for Innovative New Diagnostics forms Collaboration with Eiken Chemical
- WayPoint and Global Rapid Diagnostic Leader Enter into an Agreement
- Akers Biosciences Enters into a Distribution Agreement with Alco Industries
- Celsis and BioVentures Enter into Licensing Agreement
- Thermo Electron Inks Pact with Genomic Profiling Systems
- Abbott and OraSure Enters into Agreement for OraQuick ADVANCE Rapid HIV-1/2 Test
- bioMerieux Signs Agreement with Novel Diagnostics
- Dade Behring Bags FDA Approval for Antimicrobial Susceptibility Test Panels
- OraSure Bags HCV Patent License from Chiron and Ortho- Clinical Diagnostics
- BD Diagnostics Receives FDA Approval for BD Directigen(tm) EZ Flu A+B Test
- BD Diagnostics Bags FDA Clearance for BBL(tm) CHROMagar(tm) MRSA Product
- MedMira Obtains Rights to Market Rapid HIV Tests in Guizhou Province, China
- Gen-Probe Obtains FDA Clearance for PROCLEIX(r) West Nile Virus Assay
- Medical Services International Secures Clearance for Rapid Test Kits
- Medical Services International Receives Exclusive Marketing Rights for TB Test Kit
- Adaltis Receives Orders for HIV Rapid Tests from China
- MedCap Bags Exclusive Distribution Rights for Syphilis Rapid Test
- Genomic Profiling Systems Obtains NIAID Funds to Develop Testing Platform
- Gen-Probe Obtains US Patent for Automated Process for Nucleic Acid Testing
- Bio-Rad Receives Approval for HIV-1/HIV-2 Rapid Test
11. FOCUS ON SELECT GLOBAL PLAYERS
- Abbott Laboratories (USA)
- Abbott Diagnostics (USA)
- Alere Inc. (US)
- Becton Dickinson and Company (USA)
- bioMerieux SA (France)
- bioMerieux, Inc. (USA)
- Bio-Rad Laboratories, Inc (USA)
- Cellabs Pty Ltd (Australia)
- Celsis International Plc (UK)
- Coris BioConcept (Belgium)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Gen-Probe Inc. (USA)
- MedMira, Inc. (Canada)
- Meridian Biosciences, Inc. (USA)
- Orasure Technologies, Inc. (USA)
- Orion Diagnostica Oy (Finland)
- Quidel Corp. (USA)
- Sekisui Diagnostics (Japan)
- Siemens Healthcare Diagnostics, Inc. (USA)
- Thermo Fisher Scientific, Inc. (USA)
- Remel, Inc. (USA)
- Oxoid Limited (UK)
12. GLOBAL MARKET PERSPECTIVE
- Table 7: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 8: World Historic Review for Automated and Rapid Microbiological Tests by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 9: World 15-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 10: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 11: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 12: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 13: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 14: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 15: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Percentage Breakdown of Revenues for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 16: World Recent Past, Current & Future Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 17: World Historic Review for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 18: World 15-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
- Table 19: World Recent Past, Current & Future Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 20: World Historic Review for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 21: World 15-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 22: World Recent Past, Current & Future Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 23: World Historic Review for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 24: World 15-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 25: World Recent Past, Current & Future Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 26: World Historic Review for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 27: World 15-Year Perspective for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 28: World Recent Past, Current & Future Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 29: World Historic Review for GC/Chlamydia Rapid Tests (*) in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 30: World 15-Year Perspective for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 31: World Recent Past, Current & Future Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 32: World Historic Review for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 33: World 15-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 34: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 35: World Historic Review for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 36: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
13. THE UNITED STATES
- A. Market Analysis
- A Current & Future Analysis
- Rapid Microbiology Tests - A Competitive Profile
- Consolidation in the Automated and Rapid Microbiological Tests Market
- Bioterrorism Tests - Gaining Prominence
- Tracking Trends Across Product Segments
- STD Rapid Tests
- Market Share Trends of Leading Players
- Table 37: Leading Players in the US Market for GC/Chlamydia Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Gen-Probe, Abbott, Becton Dickinson and Roche (includes corresponding Graph/Chart)
- Table 38: Leading Players in the US Market for Chlamydia Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Thermo Fischer Scientific, Alere ,and Quidel (includes corresponding Graph/Chart)
- Table 39: Leading Players in the US Market for Syphilis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Alere, and Others (includes corresponding Graph/Chart)
- Leading Players in HIV Rapid Testing Market
- Gastrointestinal Rapid Tests
- Market Share Data of Leading Players
- Table 40: Leading Players in the US Market for C. Difficile Rapid Tests (2010) -Percentage Breakdown of Value Sales by Company for Alere, Meridian Biosciences, BioSite, Becton Dickinson, Thermo Fischer Scientific, and Others (includes corresponding Graph/Chart)
- Table 41: Leading Players in the US Market for Cryptosporidium Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes correspondingGraph/Chart)
- Table 42: Leading Players in the US Market for Rotavirus Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)
- Table 43: Leading Players in the US Market for Giardia Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes corresponding Graph/Chart)
- Respiratory Rapid Tests
- Competition
- Market Share Data of Leading Players
- Table 44: Leading Players in the US Market for Influenza Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Quidel, Becton Dickinson, Thermo Fischer Scientific and Others (includes corresponding Graph/Chart)
- Table 45: Leading Players in the US Market for RSV Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Binax,,Thermo Fischer Scientific and Others (includes corresponding Graph/Chart)
- Table 46: Leading Players in the US Market for Tuberculosis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Gen-Probe and Becton Dickinson (includes corresponding Graph/Chart)
- Table 47: Leading Players in the US Market for M. Pneumoniae Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, and Remel, Inc. (includes corresponding Graph/Chart)
- Table 48: Leading Players in the US Market for Mononucleosis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Alere, Remel, Quidel, and Others (includes corresponding Graph/Chart)
- Streptococcus Infection Rapid Tests
- Market Share Data of Leading Players
- Table 49: Leading Players in the US Market for Streptococcus A Rapid Tests (2010) -Percentage Breakdown of Value Sales by Company for Quidel, Thermo Fischer Scientific, Becton Dickinson, and Others (includes corresponding Graph/Chart)
- A Peek into the Testing Practices of the US Food Industry
- B. Market Analytics
- Table 50: US Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 51: US Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 52: US 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 53: US Recent Past, Current & Future Analysis for Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 54: US Historic Review for Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 55: US 15-Year Perspective for Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
14. EUROPE
- A. Market Analysis
- A Current & Future Analysis
- European Market Primer
- What Drives the Requirement Patterns of End-Users?
- Competitive Profile
- Trends & Issues
- Proliferation of Automated, and Rapid Tests in Europe
- European Automated Market
- Probe Tests: "A Crack in the Future of Rapid Tests"
- Trends Across Product Segments
- GC/Chlamydia Rapid Tests
- Streptococcal Infection (Strep A) Rapid Tests
- Automated Tuberculosis Systems Market
- B. Market Analytics
- Table 56: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 57: European Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 58: European 15-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Revenues for France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 59: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 60: European Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 61: European 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
14a. FRANCE
- A. Market Analysis
- A Current & Future Analysis
- bioMerieux: A Key Player
- B. Market Analytics
- Table 62: French Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 includes corresponding Graph/Chart)
- Table 63: French Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 64: French 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
14b. GERMANY
- A. Market Analysis
- A Current & Future Analysis
- Competitive Structure
- B. Market Analytics
- Table 65: German Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 66: German Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 67: German 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
14c. ITALY
- A. Market Analysis
- A Current & Future Analysis
- B. Market Analytics
- Table 68: Italian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 69: Italian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 70: Italian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
14d. THE UNITED KINGDOM
- A. Market Analysis
- A Current & Future Analysis
- Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics
- B. Market Analytics
- Table 71: UK Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 72: UK Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 73: UK 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
14e. SPAIN
- A. Market Analysis
- A Current & Future Analysis
- B. Market Analytics
- Table 74: Spanish Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 75: Spanish Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 76: Spanish 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
14f. RUSSIA
- A. Market Analysis
- A Current & Future Analysis
- B. Market Analytics
- Table 77: Russian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 78: Russian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 79: Russian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
14g. REST OF EUROPE
- A. Market Analysis
- A Current & Future Analysis
- B. Market Analytics
- Table 80: Rest of Europe Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 81: Rest of Europe Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 82: Rest of Europe 15-Year Perspective for Automated & Rapid Microbiological Tests by Product Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
15. REST OF WORLD
- A. Market Analysis
- A Current & Future Analysis
- Latin America
- Asia-Pacific - The Next Epicenter for the AIDS Epidemic
- Demand for Advanced Microbiology Instruments and Testing Methods Set to Grow in India
- B. Market Analytics
- Table 83: Rest of World Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
- Table 84: Rest of World Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 85: Rest of World 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
|
 |
